


Revaprazan hydrochloride

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-N7067 | | |
| CAS No.: | 178307-42-1 | | |
| Molecular Formula: | C ₂₂ H ₂₄ ClFN ₄ | | |
| Molecular Weight: | 398.9 | | |
| Target: | Bacterial; COX | | |
| Pathway: | Anti-infection; Immunology/Inflammation | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (20.88 mM; Need ultrasonic)

| Concentration | Mass | | |
|---------------|-----------|------------|------------|
| | 1 mg | 5 mg | 10 mg |
| 1 mM | 2.5069 mL | 12.5345 mL | 25.0689 mL |
| 5 mM | 0.5014 mL | 2.5069 mL | 5.0138 mL |
| 10 mM | 0.2507 mL | 1.2534 mL | 2.5069 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Revaprazan hydrochloride is a novel acid pump antagonist (APA). Revaprazan hydrochloride reduces COX-2 expression and has significant anti-inflammatory actions activities in *H. pylori* infection^[1].

IC₅₀ & Target

Acid pump; COX-2^[1]

REFERENCES

[1]. Lee JS, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against *Helicobacter pylori*-induced COX-2 expression by inactivating Akt signaling. *J Clin Biochem Nutr.* 2012 Sep;51(2):77-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444
Email: customerservice@lifetechindia.com Website: www.lifetechindia.com